STOCK TITAN
  1. Home
  2. Sec-filings
  3. DERM
  4. [Form 4] Journey Medical Corporation Insider Trading Activity

Journey Medical Strengthens CEO Commitment with Major Equity Grant Package

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Journey Medical Corp reported significant insider activity as President & CEO Claude Maraoui received new equity compensation awards on June 17, 2025. The transactions include:

  • 49,277 restricted stock units granted at $0, vesting in three equal annual installments from January 2026 to January 2028
  • 82,915 stock options granted with a strike price of $6.31, also vesting over three years from January 2026 to January 2028

Following these transactions, Maraoui beneficially owns 2,397,590 shares directly, including previously granted restricted stock units. As both a Director and CEO, this equity compensation aligns with long-term shareholder interests through a three-year vesting schedule. The grants were made under the company's 2015 Stock Plan, demonstrating continued executive retention efforts.

Positive

  • CEO Claude Maraoui received substantial equity incentive package worth approximately $1.2M, including 49,277 RSUs and 82,915 stock options at $6.31 strike price, aligning long-term interests with shareholders

Negative

  • None.
Insider Maraoui Claude
Role President & CEO
Type Security Shares Price Value
Grant/Award Stock Option (Right to Buy) 82,915 $0.00 --
Grant/Award Common Stock, $0.0001 par value 49,277 $0.00 --
Holdings After Transaction: Stock Option (Right to Buy) — 82,915 shares (Direct); Common Stock, $0.0001 par value — 2,397,590 shares (Direct)
Footnotes (1)
  1. On June 17, 2025, the reporting person was granted 49,277 restricted stock units pursuant to the Issuer's 2015 Stock Plan, as amended, that will vest in accordance with the following schedule: 16,426 shares on January 1, 2026, 16,426 shares on January 1, 2027 and 16,425 shares on January 1, 2028. Includes restricted stock units, which vest over various time periods. On June 17, 2025, the reporting person was granted 82,915 stock options pursuant to the Issuer's 2015 Stock Plan, as amended, that will vest in accordance with the following schedule: 27,638 shares on January 1, 2026, 27,638 shares on January 1, 2027 and 27,639 shares on January 1, 2028.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →

FAQ

How many restricted stock units (RSUs) did DERM's CEO Claude Maraoui receive on June 17, 2025?
Claude Maraoui received 49,277 restricted stock units on June 17, 2025, which will vest in three tranches: 16,426 shares on January 1, 2026, 16,426 shares on January 1, 2027, and 16,425 shares on January 1, 2028.

What is the exercise price of stock options granted to DERM's CEO in June 2025?
The stock options were granted with an exercise price of $6.31 per share and will expire on June 17, 2035.

How many DERM shares does Claude Maraoui beneficially own after the June 2025 transactions?
Following the reported transactions, Claude Maraoui beneficially owns 2,397,590 shares directly, which includes various restricted stock units that vest over different time periods.

What is the vesting schedule for DERM CEO's June 2025 stock option grant?
The 82,915 stock options granted on June 17, 2025, will vest in three approximately equal tranches: 27,638 shares on January 1, 2026, 27,638 shares on January 1, 2027, and 27,639 shares on January 1, 2028.

What positions does Claude Maraoui hold at Journey Medical Corporation (DERM)?
Claude Maraoui serves as both a Director and President & CEO of Journey Medical Corporation (DERM).
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Maraoui Claude
(Last) (First) (Middle)
C/O JOURNEY MEDICAL CORPORATION
9237 E VIA DE VENTURA BLVD., SUITE 105
(Street)
SCOTTSDALE AZ 85258
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Journey Medical Corp [ DERM ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
X Officer (give title below) Other (specify below)
President & CEO
3. Date of Earliest Transaction (Month/Day/Year)
06/17/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock, $0.0001 par value 06/17/2025 A 49,277(1) A $0 2,397,590(2) D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy) $6.31 06/17/2025 A 82,915 (3) 06/17/2035 Common Stock, $0.0001 par value 82,915 $0 82,915 D
Explanation of Responses:
1. On June 17, 2025, the reporting person was granted 49,277 restricted stock units pursuant to the Issuer's 2015 Stock Plan, as amended, that will vest in accordance with the following schedule: 16,426 shares on January 1, 2026, 16,426 shares on January 1, 2027 and 16,425 shares on January 1, 2028.
2. Includes restricted stock units, which vest over various time periods.
3. On June 17, 2025, the reporting person was granted 82,915 stock options pursuant to the Issuer's 2015 Stock Plan, as amended, that will vest in accordance with the following schedule: 27,638 shares on January 1, 2026, 27,638 shares on January 1, 2027 and 27,639 shares on January 1, 2028.
/s/ Ramsey Alloush, attorney-in-fact 06/20/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR